Transcatheter Technologies GmbH, a emerging medical device company that is developing a next-generation transcatheter aortic heart valve prosthesis, has announced the successful first-in-human implantation of its transapical TRINITY aortic valve designed to be the world's best repositionable heart valve. "A major limitation of existing transcatheter aortic heart valves is that they cannot be repositioned once implanted. Trinity, however, is designed to solve this difficult problem," said Wolfgang Goetz, MD, PhD, CEO, a cardiac surgeon by training...
More...
More...